UK Neovascular Age-Related Macular Degeneration Database. Report 6: time to retreatment after a pause in therapy. Outcomes from 92 976 intravitreal ranibizumab injections. Issue 12 (30th March 2016)

• Record Type: Journal Article
• Authors: Madhusudhana, Krishnappa C; Lee, Aaron Y; Keane, Pearse A; Chakravarthy, Usha; Johnston, Robert L; Egan, Catherine A; Sim, Dawn; Zarranz-Ventura, Javier; Tufail, Adnan; McKibbin, Martin
• Other Names: author non-byline.; Tufail Adnan author non-byline.; Johnston Robert author non-byline.; Akerele Toks author non-byline.; McKibbin Martin author non-byline.; Downey Louise author non-byline.; Natha Salim author non-byline.; Chakravarthy Usha author non-byline.; Bailey Clare author non-byline.; Khan Rehna author non-byline.; Antcliff Richard author non-byline.; Armstrong Stewart author non-byline.; Varma Atul author non-byline.; Kumar Vineeth author non-byline.; Tsaloumas Marie author non-byline.; Mandal Kaveri author non-byline.; Xing Wen author non-byline.; Bunce Catey author non-byline.
• Is Part Of: British journal of ophthalmology. Volume 100:Issue 12(2016)
• Page Start: 1617
• Page End: 1622
• Publication Date: 2016-03-30
• Subjects: Degeneration -- Macula -- Neovascularisation -- Retina -- Treatment Medical; Ophthalmology -- Periodicals; 617.7
• DOI: 10.1136/bjophthalmol-2015-308077
• Languages: English
• ISSNs: 0007-1161

Abstract

Abstract : Background/aims: To study the time to retreatment in eyes with neovascular age-related macular degeneration (nAMD) that had been treatment-free for intervals of 3 months, 6 months, 9 months and 12 months during the maintenance phase of ranibizumab therapy within the UK National Health Service. Methods: In this multicentre national nAMD database study, structured data were collected from 14 centres (involving 12 951 eyes receiving 92 976 ranibizumab injections). Patients were treated with three fixed, monthly injections in a loading phase of treatment, followed by a pro re nata retreatment regimen in a maintenance phase. Eyes with a treatment-free interval (TFI) of 3 months, 6 months, 9 months or 12 months in the maintenance phase were identified and the time to retreatment after these TFIs was determined. Results: The time to retreatment for the 20th and 50th centiles was 0.58/2.54 months after a 3-month TFI, 2.07/9.62 months after a 6-month TFI, 3.69/15.84 months after a 9-month TFI and 5.90/22.49 months after a 12-month TFI. Following a TFI of 3 months, 6 months, 9 months and 12 months, 68%, 44%, 31% and 21% of eyes required retreatments after an additional 6 months of follow-up, respectively. Similarly, after 12 months of follow-up, 77%, 56%, 43% and 34% of these eyes required retreatment. Conclusions: This study provides times to retreatment in eyes with nAMD that have been treatment-free for intervals of 3–12 months and demonstrates the likelihood of repeat therapy within the next year, even after a TFI of 12 months. These outcomes can help plan appropriate follow-up intervals for patients who have been treatment-free for intervals of up to 12 months.